![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Evaluation of Drug-Drug Interaction Between Sofosbuvir/Velpatasvir and Rifaximin in HCV-Infected Subjects with Moderate Hepatic Impairment
|
|
|
Reported by Jules Levin
17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy June 8-10, 2016, Washington, DC, USA
Erik Mogalian, Brian Kirby, Liyun Ni, Shu-Min Chuang, John McNally, and Anita Mathias
Gilead Sciences, Foster City, CA
AASLD: Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir and Velpatasvir (GS-5816) and HIV Antiretoviral Therapies - (12/07/15)
EASL: Drug-Drug Interaction Profile of Sofosbuvir/Velpatasvir Fixed-Dose Combination
Sofosbuvir/velpatasvir - (06/07/16)
![Clin1](../images/061016/061016-6/Clin1.gif)
![Clin2](../images/061016/061016-6/Clin2.gif)
![Clin3](../images/061016/061016-6/Clin3.gif)
![Clin4](../images/061016/061016-6/Clin4.gif)
![Clin5](../images/061016/061016-6/Clin5.gif)
![Clin6](../images/061016/061016-6/Clin6.gif)
![Clin7](../images/061016/061016-6/Clin7.gif)
![Clin8](../images/061016/061016-6/Clin8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|